What the PROMPT Study Taught Us About Multiplex Genetic Testing

The PROMPT Study — the Prospective Registry Of MultiPlex Testing — was built to answer a question that single-institution testing could not: when a multi-gene panel returns a variant of uncertain significance, what does it actually mean? By pooling patients across institutions, the registry assembled enough cases to begin reclassifying ambiguous variants on evidence rather than guesswork.

That mission mattered because multiplex panels created a new problem even as they solved an old one. Testing many hereditary-cancer genes at once surfaced far more variants of uncertain significance than the old single-gene BRCA tests ever did. Each VUS is an open question for a patient and a counselor, and answering it requires data at scale — exactly what a registry provides.

The enduring lesson, though, is upstream of interpretation. A registry is only as good as the samples feeding it, and a panel that fails at intake produces no data to pool. Reliable multiplex testing begins with the collection tools every reliable panel depends on, captured and stabilized correctly before any sequencer is involved.

That is the through-line from the PROMPT Study to today’s genetic diagnostics: the quality of the answer is set at the moment of collection. Standardizing collection hardware across a program is the cheapest, highest-leverage quality control a multi-site testing effort has.